Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 10/20 | 0.67 |
| ▸ | LPAR2 | Q9HBW0 | 7/20 | 0.67 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.67 |
| ▸ | CETP | P11597 | 4/20 | 0.57 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7184523 | 1.00 | LPAR3 (0.67) | LPAR3LPAR2LPAR1CETPPLA2G2D | |
| SCHEMBL7629069 | 1.00 | LPAR3 (0.67) | LPAR3LPAR2LPAR1CETPPLA2G2D | |
| SCHEMBL524493 | 1.00 | LPAR3 (0.67) | LPAR3LPAR2LPAR1CETPPLA2G2D | |
| SCHEMBL2185856 | 1.00 | LPAR3 (0.67) | LPAR3LPAR2LPAR1CETPPLA2G2D | |
| SCHEMBL1672718 | 1.00 | LPAR3 (0.67) | LPAR3LPAR2LPAR1CETPPLA2G2D | |
| SCHEMBL15282921 | 1.00 | LPAR3 (0.67) | LPAR3LPAR2LPAR1CETPPLA2G2D | |
| SCHEMBL10949658 | 1.00 | LPAR3 (0.67) | LPAR3LPAR2LPAR1CETPPLA2G2D | |
| SCHEMBL811888 | 1.00 | LPAR3 (0.67) | LPAR3LPAR2LPAR1CETPPLA2G2D | |
| SCHEMBL379005 | 1.00 | LPAR3 (0.67) | LPAR3LPAR2LPAR1CETPPLA2G2D | |
| SCHEMBL29194023 | 1.00 | LPAR3 (0.67) | LPAR3LPAR2LPAR1CETPPLA2G2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150030541-A1 | NANOPARTICLE PEG MODIFICATION WITH H-PHOSPHONATES | MNK 2011 LLC (F/K/A MALLINCKRODT INC.) | 2015-01-29 | — | — | US | disclosed |
| US-8889657-B2 | Nanoparticle PEG modification with H-phosphonates | MALLINCKRODT LLC (US) | 2014-11-18 | — | — | US | disclosed |
| EP-2750712-A2 | NANOPARTICLE PEG MODIFICATION WITH H-PHOSPHONATES | Mallinckrodt LLC (US) | 2014-07-09 | — | — | EP | disclosed |
| US-20130066086-A1 | NANOPARTICLE PEG MODIFICATION WITH H-PHOSPHONATES | MALLINCKRODT LLC (US) | 2013-03-14 | — | — | US | disclosed |
| WO-2013033438-A2 | NANOPARTICLE PEG MODIFICATION WITH H-PHOSPHONATES | MALLINCKRODT LLC (US) | 2013-03-07 | — | — | WO | disclosed |
| EP-0765913-B1 | Process for the preparation of lactic acid-based polyester compositions | DAINIPPON INK & CHEMICALS (JP) | 2002-08-28 | — | — | EP | disclosed |
| US-6169046-B1 | ABSORBABLE BARRIER MEMBRANE FOR GUIDED TISSUE REGENERATION COMPRISING A LACTIC COPOLYESTER IN WHICH A POLYMERIZATION CATALYST IS DEACTIVATED | DIRECTOR-GENERAL OF NATIONAL INSTITUTE FOR RESEARCH IN ORGANIC MATERIALS (JP) | 2001-01-02 | — | — | US | disclosed |
| US-6110578-A | STRUCTURAL UNIT DERIVED FROM HYDROXYCARBOXYLIC ACID, A STRUCTURAL UNIT DERIVED FROM MOLECULAR WEIGHT INCREASING AGENT AND/OR A STRUCTURAL UNIT DERIVED FROM POLYMERIZATION CATALYST DEACTIVATOR. | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2000-08-29 | — | — | US | disclosed |
| US-6037384-A | POLYLACTONE AND POLYMERIZATION CATALYST DEACTIVATOR; BIODEGRADABLE, STORAGE STABILITY, HEAT RESISTANCE, IMPACT STRENGTH, MOLDABILITY; PACKAGING, INSULATION, CUSHIONS | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2000-03-14 | — | — | US | disclosed |
| US-5955529-A | POLYESTER WITH UNITS FROM LACTIC ACID, DICARBOXYLIC ACIDS AND DIOLS; CALCIUM PHOSPHATE-BASED COMPOUND | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1999-09-21 | — | — | US | disclosed |
| US-5686540-A | Process for the preparation of lactic acid-based polyester | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1997-11-11 | — | — | US | disclosed |
| EP-0765913-A1 | Process for the preparation of lactic acid-based polyester compositions | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1997-04-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150030541-A1 | NANOPARTICLE PEG MODIFICATION WITH H-PHOSPHONATES | PHOSPHO1, PHPT1, HPSE | LPAR3 679/4885LPAR2 1113/4885LPAR1 773/4885 |
| US-20130066086-A1 | NANOPARTICLE PEG MODIFICATION WITH H-PHOSPHONATES | PHOSPHO1, PHPT1, HPSE | LPAR3 679/4885LPAR2 1113/4885LPAR1 773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.